Rebecca Taub, President, R&D, and CMO at MADRIGAL PHARMACEUTICALS, INC. (MDGL), sold 142,641 shares at $240.11 ($34.8M) on 2024-04-05, disclosed to the SEC on 2024-04-05.
Scheduled sale ($34.8M) by President, R&D, and CMO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $242.00 | 135 | $33K | 0.1% |
| 2 | $243.68 | 2,634 | $642K | 1.8% |
| 3 | $243.68 | 2,634 | $642K | 1.8% |
| 4 | $244.68 | 4,070 | $996K | 2.9% |
| 5 | $244.68 | 4,070 | $996K | 2.9% |
| 6 | $245.34 | 18,917 |
| $4.6M |
| 13.3% |
| 7 | $245.34 | 18,917 | $4.6M | 13.3% |
| 8 | $246.32 | 2,089 | $515K | 1.5% |
| 9 | $246.32 | 2,089 | $515K | 1.5% |
| 10 | $240.88 | 4,200 | $1.0M | 2.9% |
| 11 | $241.85 | 5,619 | $1.4M | 3.9% |
| 12 | $241.85 | 5,619 | $1.4M | 3.9% |
| 13 | $242.71 | 3,085 | $749K | 2.2% |
| 14 | $242.71 | 3,085 | $749K | 2.2% |
| 15 | $244.01 | 435 | $106K | 0.3% |
| 16 | $244.01 | 435 | $106K | 0.3% |
| 17 | $245.06 | 2,734 | $670K | 1.9% |
| 18 | $245.06 | 2,734 | $670K | 1.9% |
| 19 | $246.01 | 1,653 | $407K | 1.2% |
| 20 | $246.01 | 1,653 | $407K | 1.2% |
| 21 | $247.23 | 711 | $176K | 0.5% |
| 22 | $247.23 | 711 | $176K | 0.5% |
| 23 | $248.23 | 100 | $25K | 0.1% |
| 24 | $240.11 | 1,643 | $395K | 1.1% |
| 25 | $240.11 | 1,643 | $395K | 1.1% |
| 26 | $241.14 | 700 | $169K | 0.5% |
| 27 | $242.61 | 8,817 | $2.1M | 6.1% |
| 28 | $242.61 | 8,817 | $2.1M | 6.1% |
| 29 | $243.33 | 8,989 | $2.2M | 6.3% |
| 30 | $243.33 | 8,989 | $2.2M | 6.3% |
| 31 | $244.45 | 2,079 | $508K | 1.5% |
| 32 | $244.45 | 2,079 | $508K | 1.5% |
| 33 | $245.53 | 5,278 | $1.3M | 3.7% |
| 34 | $245.53 | 5,278 | $1.3M | 3.7% |
| Total | $244.02 avg | 142,641 | $34.8M | 100% |
| Filing → |
| MDGL | SELL | 2026-01-20 | $1.1M | — | Filing → |
| MDGL | SELL | 2026-01-13 | $18.9M | — | Filing → |
| MDGL | SELL | 2026-01-13 | $242K | — | Filing → |